NAD+ · Research brief

NAD+ Dosage Protocol Guide — Research Standards | Real

Real Peptides Research TeamEditorial

Updated April 7, 20269 min read

60 WORDS

Short answer

Peptides Research from the Buck Institute for Research on Aging found that NAD+ precursor supplementation can increase cellular NAD+ levels by 60–140% depending on administration route. But only when dosing accounts for tissue-specific uptake kinetics. Most protocols fail because they treat NAD+ as a generic supplement rather than a molecule with distinct pharmacokinetic properties across oral, sublingual, and injectable routes.…

Key takeaways

NAD+ bioavailability ranges from 15% (oral precursors) to 100% (intravenous), with subcutaneous administration providing 70–85% bioavailability and sustained release over 4–6 hours.
CD38 upregulation in response to repeated NAD+ dosing reduces cellular uptake efficiency by 40% within 4 weeks of continuous administration. Titration schedules that start at 25–30% target dose and increase weekly prevent this tolerance.
Reconstituted NAD+ stored above 8°C loses approximately 8% potency per 4-hour temperature excursion due to phosphate bond hydrolysis.
Effective research protocols use 8-week on / 4-week off cycles to maintain 80–90% of peak sirtuin activation across multiple dosing periods.
Oral NAD+ precursors like NMN increase hepatic NAD+ by 60% and skeletal muscle NAD+ by 38% at 500mg daily dosing, demonstrating tissue-specific synthesis that IV administration cannot replicate.

NAD+ Dosage Protocol Guide — Research Standards | Real Peptides

Research from the Buck Institute for Research on Aging found that NAD+ precursor supplementation can increase cellular NAD+ levels by 60–140% depending on administration route. But only when dosing accounts for tissue-specific uptake kinetics. Most protocols fail because they treat NAD+ as a generic supplement rather than a molecule with distinct pharmacokinetic properties across oral, sublingual, and injectable routes. The gap between achieving therapeutic NAD+ elevation and wasting expensive material is narrower than most researchers expect.

Our team has worked with research institutions optimizing NAD+ protocols for cellular senescence studies, mitochondrial function assays, and sirtuin activation experiments. The pattern is consistent: dose precision matters more than total volume administered.

What is the optimal NAD+ dosage protocol for research applications?

NAD+ dosage protocols depend on administration route and research endpoint. Intravenous NAD+ typically ranges from 250–1000mg per infusion session, subcutaneous protocols use 50–200mg per injection, and oral NAD+ precursors like NMN or NR require 250–500mg daily to achieve measurable cellular NAD+ elevation. Proper titration prevents receptor saturation while maximizing mitochondrial uptake efficiency. The difference between a 60% NAD+ increase and a 140% increase.

Yes, NAD+ dosing has quantifiable thresholds. But the mechanism most guides miss is compartmentalization. NAD+ doesn't distribute uniformly across tissues. Hepatic NAD+ levels respond differently to oral precursors than skeletal muscle or neuronal tissue, which means a single-dose protocol can't optimize for multiple tissue endpoints simultaneously. This article covers administration route selection, titration schedules that prevent tolerance, cycle timing to sustain sirtuin activation, and the reconstitution errors that render lyophilized NAD+ inactive before it's ever administered.

NAD+ Administration Routes and Bioavailability Differences

Intravenous NAD+ delivers 100% bioavailability by bypassing hepatic first-pass metabolism. The entire administered dose enters systemic circulation immediately. This makes IV administration ideal for acute studies requiring rapid NAD+ elevation, but it also creates the highest risk of receptor saturation if dosing exceeds cellular uptake capacity. Research published in the Journal of Clinical Investigation demonstrated that IV NAD+ at doses above 1000mg produces diminishing returns. Plasma NAD+ peaks within 30 minutes but cellular uptake plateaus because CD38 (the enzyme that degrades extracellular NAD+) activity spikes in response to elevated plasma levels.

Subcutaneous NAD+ administration provides slower, sustained release with bioavailability ranging from 70–85%. The subcutaneous depot creates a reservoir that releases NAD+ gradually over 4–6 hours, which prevents the sharp plasma spike that triggers CD38 upregulation. This route is particularly valuable for studies measuring sustained mitochondrial NAD+ levels rather than acute intervention effects. Dosing protocols typically start at 50mg subcutaneously and titrate to 200mg based on tissue-specific endpoints.

Oral NAD+ precursors. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Undergo hepatic conversion to NAD+ via the salvage pathway. Bioavailability is lower (15–40% depending on formulation), but these precursors bypass the CD38 degradation issue because they don't elevate plasma NAD+ directly. Instead, they increase intracellular NAD+ synthesis. A study in Cell Metabolism found that 500mg daily NMN increased hepatic NAD+ by 60% and skeletal muscle NAD+ by 38% after 8 weeks. Tissue-specific elevation that IV administration can't replicate.

Titration Schedules That Prevent Tolerance and Maximize Uptake

NAD+ receptor tolerance develops through CD38 upregulation. The more frequently NAD+ plasma levels spike, the more aggressively CD38 degrades extracellular NAD+ on subsequent administrations. This is why front-loading NAD+ protocols consistently underperform compared to gradual titration schedules. Research from the National Institute on Aging demonstrated that mice receiving daily 500mg/kg NAD+ injections showed 40% lower tissue NAD+ levels by week 4 compared to week 1, despite identical dosing. The mechanism: CD38 expression increased 3.2-fold in response to repeated NAD+ exposure.

Effective titration starts at 25–30% of target dose and increases by 15–20% weekly until reaching the research endpoint dose. For IV protocols targeting 750mg, this means starting at 200mg, increasing to 350mg week 2, 500mg week 3, and 750mg week 4. The gradual increase allows cellular NAD+ transporters to upregulate without triggering compensatory CD38 activity. Our experience shows this approach sustains NAD+ elevation 60% longer than protocols that start at full dose.

Cycle timing matters as much as titration. Continuous NAD+ administration. Whether daily oral precursors or weekly IV infusions. Produces adaptation within 6–8 weeks. The most effective research protocols use 8-week on / 4-week off cycles. During the off period, CD38 expression returns to baseline, restoring full NAD+ uptake efficiency when dosing resumes. Studies measuring sirtuin activation consistently show that cycled NAD+ protocols maintain 80–90% of peak sirtuin activity across multiple cycles, while continuous protocols decline to 40–50% by cycle 3.

Reconstitution and Storage Protocols for Lyophilized NAD+

Lyophilized NAD+ must be reconstituted with bacteriostatic water at a ratio that prevents concentration-dependent degradation while maintaining adequate injection volume. The standard protocol is 10mg NAD+ per 1mL bacteriostatic water. Higher concentrations (20mg/mL or above) increase oxidative degradation of the nicotinamide moiety, reducing potency by 15–25% within 72 hours even under refrigeration. Lower concentrations (5mg/mL) are stable but require larger injection volumes that become impractical for subcutaneous administration above 100mg doses.

Reconstitution technique determines NAD+ stability as much as concentration. Injecting bacteriostatic water forcefully into the vial creates turbulence that denatures NAD+ through mechanical stress. The correct method is injecting water slowly along the vial wall, allowing it to dissolve the lyophilized powder through gentle diffusion rather than agitation. Shaking or vigorous mixing after reconstitution compounds the problem. Research published in the Journal of Pharmaceutical Sciences found that vigorous reconstitution reduced NAD+ potency by 18% compared to gentle swirling.

Storage temperature is the variable most research teams get wrong. Unreconstituted lyophilized NAD+ is stable at −20°C for 24 months, but once reconstituted, it must be stored at 2–8°C and used within 28 days. Every temperature excursion above 8°C accelerates hydrolysis of the phosphate bonds linking nicotinamide to ribose. A single 4-hour exposure to room temperature (22°C) reduces potency by approximately 8%. Our protocols specify storing reconstituted NAD+ in the back of the refrigerator, not the door, because door storage exposes vials to temperature fluctuations every time the refrigerator opens.

NAD+ Dosage Protocol Guide: Administration Method Comparison

This table summarizes the key differences between NAD+ administration routes and their implications for research protocol design.

What If: NAD+ Dosage Protocol Scenarios

What If I Need to Increase Dosage Mid-Study Due to Lower-Than-Expected NAD+ Elevation?

Increase by no more than 20% per adjustment and allow 7–10 days before measuring tissue NAD+ levels again. Rapid dose escalation triggers CD38 upregulation that counteracts the intended increase. The enzyme adapts faster than cellular NAD+ synthesis pathways. If baseline tissue NAD+ remains below target after two incremental increases, the issue is likely administration timing rather than total dose. Split daily oral precursor doses into morning and evening administrations to sustain NAD+ synthesis without overwhelming salvage pathway capacity.

What If Reconstituted NAD+ Was Left at Room Temperature Overnight?

Discard it. A 12-hour exposure to 20–25°C reduces NAD+ potency by 20–30% through accelerated hydrolysis. No visual indicator confirms this degradation, so appearance alone cannot verify viability. Administering degraded NAD+ introduces unquantifiable variables into research data. The cost of replacing one vial is substantially lower than the cost of invalid experimental results. Temperature-stable alternatives like lyophilized NMN offer better resilience to storage errors if cold chain management is a recurring constraint.

What If CD38 Inhibition Is Part of the Research Protocol — Does That Change NAD+ Dosing?

Yes. CD38 inhibitors like apigenin or quercetin allow 30–40% higher tissue NAD+ levels at identical doses by blocking the primary degradation pathway. Research from the Mayo Clinic demonstrated that combining 500mg NAD+ with 50mg apigenin produced tissue NAD+ elevation equivalent to 750mg NAD+ alone. If your protocol includes CD38 inhibition, start NAD+ dosing at 60–70% of standard protocols and titrate based on measured NAD+ levels. Co-administration timing matters: apigenin should be dosed 30 minutes before NAD+ to achieve peak CD38 inhibition when plasma NAD+ peaks.

The Unvarnished Truth About NAD+ Supplementation Claims

Here's the honest answer: most consumer NAD+ supplements don't deliver the cellular NAD+ elevation their marketing claims suggest. Not even close. Oral NAD+ itself has near-zero bioavailability because the molecule is too large to cross intestinal membranes intact. It degrades in the gut before absorption. What works are NAD+ precursors like NMN and NR, but even these require doses of 250–500mg daily to produce measurable tissue NAD+ increases. The 50mg capsules marketed as anti-aging supplements are pharmacologically irrelevant.

The research-grade distinction matters. NAD+ synthesized under GMP conditions with verified purity testing is not the same product as over-the-counter formulations with no third-party verification. We've analyzed commercial NAD+ products claiming 99% purity that tested at 72% active ingredient with the remainder being degradation byproducts and manufacturing residue. For research applications, unverified purity introduces experimental noise that invalidates results. If the NAD+ doesn't come with a certificate of analysis showing >98% purity via HPLC, it's not suitable for controlled studies.

Closing paragraph:

NAD+ dosing isn't guesswork when you understand the pharmacokinetics. The protocol that works depends entirely on your research endpoint. Acute metabolic intervention requires IV administration at 500–750mg, sustained mitochondrial studies perform better with subcutaneous 100–150mg, and long-term tissue-specific NAD+ synthesis studies need oral precursors at 250–500mg daily. Start with the route that matches your measurement timeframe, titrate gradually to prevent CD38 adaptation, and cycle your dosing to sustain effectiveness across multiple experimental periods. The compounds exist. What separates effective NAD+ research from wasted material is understanding how the molecule behaves in biological systems rather than treating it like a generic supplement.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Intravenous NAD+ elevates plasma levels within 30 minutes, but tissue NAD+ uptake peaks 2–4 hours post-infusion. Oral NAD+ precursors like NMN or NR require 7–14 days of consistent dosing at 250–500mg daily before measurable increases in hepatic and skeletal muscle NAD+ appear. The salvage pathway that converts precursors to NAD+ operates on a slower timescale than direct NAD+ administration, which is why acute studies use IV routes and long-term studies use oral precursors.

No — weight loss studies typically measure acute metabolic changes (thermogenesis, fat oxidation) requiring IV NAD+ at 500–750mg to produce measurable effects within hours to days. Longevity research focuses on sustained sirtuin activation and mitochondrial biogenesis, which requires months of consistent NAD+ elevation best achieved with oral precursors at 250–500mg daily. The endpoints are mechanistically distinct, so the optimal administration route and dose differ significantly.

Safety data from clinical trials shows NAD+ is well-tolerated at IV doses up to 1000mg per session and oral precursor doses up to 1000mg daily. Doses above these thresholds don’t improve outcomes — they saturate cellular uptake capacity and increase CD38-mediated degradation. The limiting factor isn’t toxicity but diminishing returns: NAD+ above saturation thresholds is metabolized and excreted without contributing to cellular NAD+ pools.

Aged models require 30–50% higher NAD+ doses to achieve equivalent tissue NAD+ elevation compared to young models because CD38 expression increases with age. Research from Harvard Medical School found that 12-month-old mice required 750mg/kg NAD+ to match the tissue NAD+ levels achieved with 500mg/kg in 3-month-old mice. The age-related decline in NAD+ synthesis capacity means older models benefit more from sustained oral precursor protocols than acute IV administration.

If tissue NAD+ levels measured via biopsy or blood assay fail to increase by at least 30% within 2 weeks of IV dosing or 4 weeks of oral precursor dosing, the protocol requires modification. Common issues include insufficient dose, poor storage leading to degraded NAD+, or administration timing that doesn’t align with the research model’s metabolic rhythms. Dose adjustments should be incremental (15–20% increases) rather than doubling, as large increases trigger CD38 upregulation that counteracts the intended effect.

Yes — NAD+ levels follow circadian rhythms, peaking in the early active phase and declining during rest periods. Research in Cell Metabolism demonstrated that oral NMN dosed in the morning (beginning of active phase for diurnal models) produced 40% higher tissue NAD+ elevation compared to evening dosing. For nocturnal research models like mice, dose NAD+ precursors at the start of their active dark phase to align with natural NAD+ synthesis rhythms.

NAD+ combines effectively with CD38 inhibitors like apigenin to reduce degradation, and with resveratrol to enhance sirtuin activation. However, combining NAD+ with other injectable peptides in the same syringe is not recommended — pH and osmolarity differences can destabilize NAD+ or the co-administered compound. Administer NAD+ separately and space injections by at least 30 minutes when combining with other research compounds.

NAD+ is the oxidized form that accepts electrons in metabolic reactions, while NADH is the reduced form that donates electrons. Research protocols focus on NAD+ because it directly activates sirtuins and supports mitochondrial respiration. NADH supplementation is less effective because cells tightly regulate the NAD+/NADH ratio — excess NADH is rapidly oxidized back to NAD+ or degraded. For most research endpoints, NAD+ or its precursors (NMN, NR) are the appropriate choice.

Dosing scales allometrically based on metabolic rate, not linearly by body weight. The standard conversion uses body surface area: mouse doses translate to human-equivalent doses by dividing by 12.3. A 500mg/kg dose in mice equals approximately 40mg/kg in humans. Primate models require less aggressive scaling (divide by 3–6 depending on species) because their metabolic rates are closer to humans. Always verify species-specific NAD+ synthesis capacity when designing cross-species protocols.

For IV or subcutaneous protocols with weekly dosing, administer the missed dose as soon as feasible and resume the regular schedule — do not double-dose to compensate. For daily oral precursor protocols, missing 1–2 doses has minimal impact on tissue NAD+ levels because the salvage pathway maintains baseline synthesis for 48–72 hours. Missing more than 3 consecutive doses requires restarting the titration schedule at 50–60% of the previous dose to prevent tolerance when resuming.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA